First Wave BioPharma, Inc. |
(Exact name of registrant as specified in its charter)
|
Delaware |
001-37853 |
46-4993860 | ||
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
777 Yamato Road, Suite 502
Boca Raton, Florida
|
33431 | |
(Address of principal executive offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
| ||
Common Stock, par value $0.0001 per share |
FWBI |
Nasdaq Capital Market |
Item 3.01. |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
First Wave BioPharma, Inc.
| |||
November 29, 2021
|
By:
|
/s/ Daniel Schneiderman
| |
Name:
|
Daniel Schneiderman
| ||
Title:
|
Chief Financial Officer
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
First Wave BioPharma Inc. published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 November 2021 21:50:04 UTC.